<DOC>
	<DOCNO>NCT00005092</DOCNO>
	<brief_summary>RATIONALE : Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . Sometimes transplanted cell reject body 's normal tissue . Transplanting donated cell treat psoralen may prevent happen . PURPOSE : Phase I trial study effectiveness chemotherapy , radiation therapy , psoralen-treated donor cell treat patient undergoing peripheral stem cell transplantation hematologic cancer .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Peripheral Stem Cell Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose T-cells photochemically treat psoralen ultraviolet A give peripheral stem cell transplantation patient hematologic malignancy bone marrow failure myelodysplastic syndrome . II . Assess toxicity treatment patient . III . Evaluate regimen term prevention graft versus host disease control malignancy patient . OUTLINE : This dose escalation , multicenter study T-cells photochemically treat psoralen ultraviolet A . Patients receive thiotepa IV 2 hour day 1 , cyclophosphamide IV 2 hour day 2 3 , whole body radiotherapy day 5-8 . Patients undergo preserved stem cell bone marrow allogeneic transplant plus psoralen treat T-cell allogeneic transplant day 9 . Cohorts 3-6 patient receive escalate dos photochemically treat T-cells maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 patient experience dose limit toxicity . Patients follow 100 day . PROJECTED ACCRUAL : A maximum 37 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Methoxsalen</mesh_term>
	<mesh_term>Furocoumarins</mesh_term>
	<mesh_term>Ficusin</mesh_term>
	<mesh_term>Amotosalen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Hematologic malignancy , include acute myeloid lymphoid leukemia FAB subtype , remission chemotherapy require bone marrow transplant OR Chronic myeloid leukemia , advance beyond first chronic phase OR Myelodysplasia , include secondary prior chemotherapy , : Granulocyte count le 500/mm3 OR Platelet count le 50,000/mm3 OR High risk cytogenetic abnormality +8 , 7 , 5 , 11q23 OR Intermediate high grade lymphoma without response initial therapy relapse OR Multiple myeloma without response initial therapy relapse OR Stage IV low grade lymphoma chronic lymphocytic leukemia achieve remission 2 regimens No aplastic anemia Related haploidentical donor ( 13 HLAA , B , and/or DR mismatch ) collection stem cell whole blood Tcells require PATIENT CHARACTERISTICS : Age : 6 month 49 year Performance status : ECOG 02 Life expectancy : Greater 12 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 1.5 mg/dL SGPT le 3 time upper limit normal Renal : Creatinine le 1.5 mg/dL Cardiovascular : Left ventricular ejection fraction least 45 % No symptom active treatment leave ventricular failure Pulmonary : Corrected DLCO least 50 % Other : No acute viral , bacterial , fungal infection No prior transfusion associate graft versus host disease No medical condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior immunotherapy interferon alfa recover No prior autologous allogeneic progenitor cell transplant Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since prior radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>adult acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>childhood acute monoblastic leukemia acute monocytic leukemia ( M5 )</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L3 childhood acute lymphoblastic leukemia</keyword>
	<keyword>T-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa negative childhood acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive , pre-B childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 adult acute lymphoblastic leukemia</keyword>
	<keyword>L2 adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>T-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B adult acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive adult acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa positive , pre-B adult acute lymphoblastic leukemia</keyword>
	<keyword>non-T , non-B , cALLa negative adult acute lymphoblastic leukemia</keyword>
	<keyword>TdT positive adult acute lymphoblastic leukemia</keyword>
	<keyword>TdT negative adult acute lymphoblastic leukemia</keyword>
	<keyword>TdT negative childhood acute lymphoblastic leukemia</keyword>
	<keyword>TdT positive childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute eosinophilic leukemia</keyword>
	<keyword>childhood acute basophilic leukemia</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>childhood acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>childhood large cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>